

IN THE CLAIMS

Claims 1-59 (Cancelled)

60. (Twice Amended) An pharmaceutical formulation, comprising Glutathione, in combination with an effective amount of one or more of a pharmaceutically acceptable physiologic nitric oxide precursor, ~~an antiviral composition,~~ and an antimicrobial composition.

61. (Previously Amended) The formulation according to claim 60, wherein the formulation acts as a vasodilator through alteration of nitric oxide metabolism.

62. (Previously Amended) The formulation method according to claim 60, wherein the formulation is effective for treating pathological vasospasm.

63. (Previously Amended) The method according to claim 60, wherein the formulation is effective for treating sexual dysfunction.

64. (Previously Amended) The formulation according to claim 60, in combination with a drug effective to treat congestive heart failure.

65. (Previously Amended) The formulation according to claim 60, wherein said formulation is in unit dosage form and comprises a physiologic nitric oxide precursor.

66. (Previously Amended) The formulation according to claim 65, wherein the nitric oxide precursor is arginine.

67. (Previously Amended) The formulation according to claim 65, wherein said formulation comprises about 500 mg reduced L-glutathione, about 200 mg ascorbic acid, and about 200 mg arginine.

68. (Previously Amended) The formulation according to claim 60, wherein the formulation comprises a nitric oxide precursor and an antiviral composition.

69. (Previously Amended) The formulation according to claim 60, wherein the nitric oxide precursor comprises an NO₂ functionality.

70. (Previously Amended) The formulation according to claim 69, wherein the nitric oxide precursor comprises an organic nitrate.

71. (Previously Amended) The formulation according to claim 60, wherein said formulation comprises a pharmaceutically acceptable antimicrobial antibiotic agent.

72. (Cancelled) The formulation according to claim 60, comprising at least one of an antiviral or antimicrobial antibiotic agent.

73. (Previously Amended) The formulation according to claim 72, wherein said antibiotic agent comprises an antibiotic having activity against mycoplasma infection.

74. (Cancelled) The formulation according to claim 72, wherein said antibiotic agent comprises a pharmaceutically acceptable antiviral composition having activity against viral infection.

75. (Previously Amended) The formulation according to claim 72, wherein said antimicrobial agent comprises an antibiotic in sufficient amount to suppress growth of a microbe and said glutathione is provided in sufficient amount to control free radical reactions associated with the microbe.

76. (Previously Amended) The pharmaceutical formulation according to claim 60, wherein said formulation is provided in an oral dosage form

77. (Previously Amended) The formulation according to claim 72, wherein said antibiotic agent comprises an aminoglycoside.

78. (Previously Amended) The formulation according to claim 72, comprising a quinolone antibiotic.

79. (Previously Amended) The formulation according to claim 72, wherein said formulation is adapted to modify vascular tone in an organism administered said formulation.

80. (Currently Amended) A pharmaceutical composition, comprising in combination glutathione, or a pharmaceutically acceptable salt or derivative thereof, and at least one of an antiviral or antimicrobial antibiotic agent, said glutathione being present in an effective amount to at least one of: serve as an effective antioxidant agent; supplement endogenous glutathione consumed as a result of administration of the pharmaceutical composition; alter cardiovascular status of a host; alter a redox status of a host; and alter a gene expression within a host, and said antiviral or antimicrobial agent being present in an effective amount to treat or prophylax a viral or microbial-associated condition of the host.

81. (Previously Added) The pharmaceutical composition according to claim 80, comprising, in unit dosage form, glutathione in an amount of at least 250 mg., a sacrificial antioxidant to preserve the glutathione in a reduced state, an effective amount of a pharmaceutically acceptable topoisomerase inhibitor, and a pharmaceutically acceptable physiologic nitric oxide precursor.

82. (Previously Added) The pharmaceutical composition according to claim 80, wherein the antioxidant comprises ascorbic acid.

83. (Previously Added) The pharmaceutical composition according to claim 80, further comprising an antibiotic having activity against mycoplasma infection.

84. (Cancelled) The pharmaceutical composition according to claim 80, further comprising an antibiotic having activity against viral infection.

85. (Previously Added) The pharmaceutical composition according to claim 80, wherein said composition is provided in an oral dosage form.

86. (Previously Added) The pharmaceutical composition according to claim 80, comprising an aminoglycoside antibiotic.

87. (Previously Added) The pharmaceutical composition according to claim 80, comprising a quinolone antibiotic.